Physicians

Department / Division
Medicine / Medicine - Oncology

Address
DUMC 3147
Durham, NC 27710

Appointment Telephone
919-660-9672, 919-684-3181 (Hereditary Cancer Clinic)

Office Telephone
919-684-3877

Fax Telephone
919-681-0874

Training

• MD, Baylor College of Medicine (Texas), 1989

Residency

• Medicine, Duke University Medical Center, 1989-1992
• Hematology-Oncology, Duke University Medical Center, 1992-1995

Fellowship

• Postdoctoral Fellow, Duke University Medical Center, 1995-1997

Clinical Interests
Breast cancer treatment; hereditary cancer syndromes; cell-cycle control alterations in cancer; breast cancer genomics

Research Interests
Basic Science:
-Germline and somatic genetic changes in cancer, particularly breast cancer. Ongoing efforts with Dr. Joseph R. Nevins in Department of Genetics.

Translational:
-Identification and management of individuals and families with hereditary cancer risk.
-Communication of cancer risk information to individuals and families.
-Breast cancer prevention.
-Optimizing management of early breast cancer.
-Treatment of metastatic breast cancer

Dr. Marcom's research has focused on two main areas. First, in the laboratory of Dr. Joseph Nevins in the Department of Genetics, he has been investigating alterations in cell cycle control in cancer. Primarily, these experiments have looked for primary alterations in the E2F family of genes, and their possible contribution to developing cancer. More recently, he has been involved with issues regarding genetic predisposition to developing cancer.

Investigations of cell cycle alterations have employed standard molecular biology techniques to analyze both cell lines and primary tumors for alterations in control of the retinoblastoma pathway, and consequent effects on E2F control.

Clinically, Dr. Marcom works as a medical oncologist in the multidisciplinary breast cancer clinic. He participates in clinical trials investigating new chemotherapeutic and biologic treatments. In addition, he is developing a new high risk, familial cancer clinic. This clinic will see patients and families thought to be at high risk of developing malignancies, and will interface with the forming Cancer Genetics Network. Patients and families will be counseled about their cancer risk, and identified for studying issues related to cancer genetics: determining penetrance of identified gene mutations, determining factors modifying genetic risk, prevention studies, etc. Finally, he also plans to be involved in clinical evaluation of drugs inhibiting tumor angiogenesis.

Areas of developing expertise include cell cycle alterations in malignancy, breast cancer, and hereditary cancer genetics.

Breast cancer, cell cycle, genetics, familial cancer, prognostic factors, angiogenesis

Industry Relationships and Collaborations (What's this?)

This faculty member has no reported relationships with industry.

Representative Publications
Bean, GR; Ibarra Drendall, C; Goldenberg, VK; Baker, JC; Troch, MM; Paisie, C; Wilke, LG; Yee, L; Marcom, PK; Kimler, BF; Fabian, CJ; Zalles, CM; Broadwater, G; Scott, V; Seewaldt, VL. Hypermethylation of the breast cancer-associated gene 1 promoter does not predict cytologic atypia or correlate with surrogate end points of breast cancer risk. Cancer Epidemiology, Biomarkers and Prevention. 2007;16:50-56. (2007) Abstract

Marcom, PK; Isaacs, C; Harris, L; Wong, ZW; Kommarreddy, A; Novielli, N; Mann, G; Tao, Y; Ellis, MJ. The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers. Breast Cancer Research and Treatment. 2007;102:43-49. (2007) Abstract

Daly, MB; Axilbund, JE; Bryant, E; Buys, S; Eng, C; Friedman, S; Esserman, LJ; Farrell, CD; Ford, JM; Garber, JE; Jeter, JM; Kohlmann, W; Lynch, PM; Marcom, PK; Nabell, LM; Offit, K; Osarogiagbon, RU; Pasche, B; Reiser, G; Sutphen, R; Weitzel, JN; National Comprehensive Cancer Network. Genetic/familial high-risk assessment: breast and ovarian. Journal of the National Comprehensive Cancer Network : JNCCN. 2006;4:156-176. (2006) Abstract

Dressman, HK; Hans, C; Bild, A; Olson, JA; Rosen, E; Marcom, PK; Liotcheva, VB; Jones, EL; Vujaskovic, Z; Marks, J; Dewhirst, MW; West, M; Nevins, JR; Blackwell, K. Gene expression profiles of multiple breast cancer phenotypes and response to neoadjuvant chemotherapy. Clinical Cancer Research. 2006;12:819-826. (2006) Abstract

Bean, GR; Scott, V; Yee, L; Ratliff-Daniel, B; Troch, MM; Seo, P; Bowie, ML; Marcom, PK; Slade, J; Kimler, BF; Fabian, CJ; Zalles, CM; Broadwater, G; Baker, JC; Wilke, LG; Seewaldt, VL. Retinoic acid receptor-beta2 promoter methylation in random periareolar fine needle aspiration. Cancer Epidemiology, Biomarkers and Prevention. 2005;14:790-798. (2005) Abstract

Burris, HA; Hurwitz, HI; Dees, EC; Dowlati, A; Blackwell, KL; O'Neil, B; Marcom, PK; Ellis, MJ; Overmoyer, B; Jones, SF; Harris, JL; Smith, DA; Koch, KM; Stead, A; Mangum, S; Spector, NL. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. Journal of Clinical Oncology. 2005;23:5305-5313. (2005) Abstract

Miller, KD; Chap, LI; Holmes, FA; Cobleigh, MA; Marcom, PK; Fehrenbacher, L; Dickler, M; Overmoyer, BA; Reimann, JD; Sing, AP; Langmuir, V; Rugo, HS. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. Journal of Clinical Oncology. 2005;23:792-799. (2005) Abstract

Spector, NL; Xia, W; Burris, H; Hurwitz, H; Dees, EC; Dowlati, A; O'Neil, B; Overmoyer, B; Marcom, PK; Blackwell, KL; Smith, DA; Koch, KM; Stead, A; Mangum, S; Ellis, MJ; Liu, L; Man, AK; Bremer, TM; Harris, J; Bacus, S. Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. Journal of Clinical Oncology. 2005;23:2502-2512. (2005) Abstract

Gradishar, WJ; Meza, LA; Amin, B; Samid, D; Hill, T; Chen, YM; Lower, EE; Marcom, PK. Capecitabine plus paclitaxel as front-line combination therapy for metastatic breast cancer: a multicenter phase II study. Journal of Clinical Oncology. 2004;22:2321-2327. (2004) Abstract

Jones, EL; Prosnitz, LR; Dewhirst, MW; Marcom, PK; Hardenbergh, PH; Marks, LB; Brizel, DM; Vujaskovic, Z. Thermochemoradiotherapy improves oxygenation in locally advanced breast cancer. Clinical Cancer Research. 2004;10:4287-4293. (2004) Abstract

Burstein, HJ; Harris, LN; Marcom, PK; Lambert-Falls, R; Havlin, K; Overmoyer, B; Friedlander, RJ; Gargiulo, J; Strenger, R; Vogel, CL; Ryan, PD; Ellis, MJ; Nunes, RA; Bunnell, CA; Campos, SM; Hallor, M; Gelman, R; Winer, EP. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. Journal of Clinical Oncology. 2003;21:2889-2895. (2003) Abstract

Partridge, AH; Burstein, HJ; Gelman, RS; Marcom, PK; Winer, EP. Do patients participating in clinical trials want to know study results?. Journal of the National Cancer Institute. 2003;95:491-492. (2003) Abstract

Skinner, CS; Schildkraut, JM; Berry, D; Calingaert, B; Marcom, PK; Sugarman, J; Winer, EP; Iglehart, JD; Futreal, PA; Rimer, BK. Pre-counseling education materials for BRCA testing: does tailoring make a difference?. Genetic Testing and Molecular Biomarkers. 2002;6:93-105. (2002) Abstract

Demark-Wahnefried, W; Peterson, BL; Winer, EP; Marks, L; Aziz, N; Marcom, PK; Blackwell, K; Rimer, BK. Changes in weight, body composition, and factors influencing energy balance among premenopausal breast cancer patients receiving adjuvant chemotherapy. Journal of Clinical Oncology. 2001;19:2381-2389. (2001) Abstract

Burstein, HJ; Ramirez, MJ; Petros, WP; Clarke, KD; Warmuth, MA; Marcom, PK; Matulonis, UA; Parker, LM; Harris, LN; Winer, EP. Phase I study of Doxil and vinorelbine in metastatic breast cancer. Annals of Oncology. 1999;10:1113-1116. (1999) Abstract

Ortel, TL; Charles, LA; Keller, FG; Marcom, PK; Oldham, HN; Kane, WH; Macik, BG. Topical thrombin and acquired coagulation factor inhibitors: clinical spectrum and laboratory diagnosis. American Journal of Hematology. 1994;45:128-135. (1994) Abstract

Kirkland, KB; Marcom, PK; Sexton, DJ; Dumler, JS; Walker, DH. Rocky Mountain spotted fever complicated by gangrene: report of six cases and review. Clinical Infectious Diseases. 1993;16:629-634. (1993) Abstract

Noebels, JL; Marcom, PK; Jalilian-Tehrani, MH. Sodium channel density in hypomyelinated brain increased by myelin basic protein gene deletion. Nature. 1991;352:431-434. (1991) Abstract